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Background: Using laser speckle flowgraphy to calculate retinal blood flow, we sought 
to measure changes in optic nerve blood flow compared to the normal fellow eye 
(relative blood flow) and changes in vision in patients with central retinal artery 
occlusions of varying duration.   
Methods:  Laser speckle flowgraphy was used to measure optic nerve blood flow in eyes 
with central retinal artery occlusions and the normal fellow eye of patients seen at Beth 
Israel Deaconess Medical Center to calculate relative blood flow. Visual acuity was 
assessed monocularly using Snellen Charts in a standardized fashion.  
Results: In healthy control patients (n=20), relative blood flow was calculated to be 1.02 
(p= 0.6843), indicating no significant difference in blood flow between eyes. In patients 
with unilateral central retinal artery occlusions (n=7), relative blood flow was calculated 
to be 0.66 ± 0.13 (p < .001), indicating on average a 33 percent loss in blood flow 
through the optic nerve head. When comparing relative blood flow values of CRAO 
patients measured within one year of vision loss versus patients when measured after 




Conclusions and Relevance: Laser Speckle Flowgraphy has been shown to be a useful 
diagnostic tool that can reliably provide quantitative information on retinal blood flow. 
Results suggest that blood flow through the optic nerve head does return over time, 
presumably as the occlusion resolves or recanalizes. Longitudinal analysis determined a 
higher relative blood flow in patients one-year post incident versus within one year. 
However no statistically significant difference in visual acuity between these groups was 
found, indicating that return of blood flow is not associated with a return in visual acuity. 
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 More than 600 million years ago, organisms developed the ability to respond to 
light. Approximately 60 million years later, during the Cambrian explosion, organisms 
began rapidly evolving and diversifying, and visual systems such as the eye first emerged 
(Lamb et al., 2007).   The eye is fundamental to the processing and function of our visual 
systems, a major sensory modality, and disease or disfunction can lead to a dramatic 
impact in the quality of life of individuals. Like any organ of the body, ischemia and 
anoxia can damage and destroy non-perfused tissues. This is of particular relevance 
when addressing the retina. The anatomy and physiology of the eye are paramount in 
understanding how disease can dramatically alter a patient’s ability to perceive light 
stimuli.  
 
Anatomy of the Eye  
 
 In humans, the eye is situated in the two bony orbits of the skull, which is 
formed from a conjoining of the articulation of the frontal bone, maxillary bone, lacrimal 
bone, nasal bone, ethmoid bone, zygomatic bone, sphenoid bone, and palatine bone of 
the skull (Wolff, 1976). Light first passes through the cornea of the eye, a dome shaped, 
transparent structure composed of highly ordered layers of collagen, and is ultimately 




the eye. The cornea is continuous with the sclera, an opaque, white structure that 
constitutes the exterior of the remainder of the globe and protects the inner structures 
of the eye from the environment (Meek & Knupp, 2015).  Light then passes through the 
anterior chamber of the eye through aqueous humor, a transparent, thin fluid which is 
encapsulated by the cornea anteriorly and the ciliary body, lens, and suspensory 
ligaments posteriorly.  It then is refracted through the lens, which is suspended from the 
surrounding ciliary body via zonular fibers and allows for a degree of accommodation as 
it is malleable and changes shaped based on the contraction or relaxation of the ciliary 
muscle (Wolff, 1976). Directly posterior to the lens is the largest chamber of the eye, the 
vitreous chamber, which contains the vitreous humor, a viscous, gel-like substance. 
Light passes through the vitreous humor last before contacting the retina, a complex, 
ordered layer of cells that include photoreceptors, neurons which are directly 
stimulated by electromagnetic radiation in the visible light spectrum. The retina is 
situated above the choroid, a highly vascularized layer that provides nutrients and 
oxygen to approximately 85% of the eye (Zeiss et al., 2018). It is the retina that 
ultimately begins the complex process of translating light stimuli into the visual 
perception of our surroundings. 
3 
Figure 1:  Major anatomical structures of the human eye. This illustrates a sagittal 
cross-sectional view of the human eye. Note that light passes through the eye beginning 
at with the cornea (left) and is refracted by both the cornea and the lens onto the retina 
(right), which surrounds the vitreous chamber.   
The Retina 
The retina is located between the vitreous humor of the posterior segment of 
the eye and the choroid, and is a complex and ordered series of epithelial, neuronal, and 
connective tissue. The retina is stratified into ten distinct layers, each containing distinct 
cell types with specific functions. Light passes through nine of the ten layers of the 
retina before coming in contact with the photoreceptors, which are located most 
posteriorly and in contact with the final layer, the retinal pigment epithelium. Light 




molecule 11-cis-retinal into all-trans-retinal through a radiation induced conformational 
change, which starts a complex signaling cascade that is continuously modified as it 
passes through the layers of the retina to ganglion cell layer. Ultimately the nerve fibers 
of the ganglion cells send signals through the optic disc and through the optic nerve for 
further processing in the thalamus and occipital lobe of the brain (Barrett et. al, 2019). 
Two distinct photoreceptor cell types are found in the mammalian retina; cone 
photoreceptors, which are used for sensing color and primarily utilized during 
phototopic vision, and rod photoreceptors, which are utilized during scotopic vision 
conditions and are important in the detection of peripheral movement (Wollf, 1976). 
The macula of the retina is located centrally and is an area of particular importance, as it 
contains the highest density of cone photoreceptors and is responsible for high 
resolution, central visual acuity (VA). Located at the center of the macula is the fovea 
centralis, a depression in the overall thickness of the retina due to the displacement of 
non-photoreceptor retinal neurons. The displacement of non-photoreceptor neurons 
allows light to contact photoreceptors cells in an unobstructed fashion and contributes 
to the high acuity of central vision in the fovea. As cone density approaches between 
200,000 to 300,000 cones per square millimeter and the photoreceptor to ganglion cell 
ratio approaches 1:1, which is thought to also contribute to the high VA in central vision 
(Mihailovic et. al., 2019). Directly peripheral to the fovea is the parafoveal and the 




Layers of the Retina 
 The retina is comprised of ten distinct layers, nine of which light passes through 
before contacting the photoreceptors responsible for transforming the stimuli into 
electrical signals. The most superficial layer of the retina is the inner limiting membrane 
followed immediately by the nerve fiber layer, which contains the axons of the ganglion 
cells. The ganglion cell layer follows, which contains the cell bodies of the ganglion cells, 
which receive, integrate, and modify signals from the remaining layers of the retina 
before transmitting information through the optic nerve to the occipital lobe. The inner 
plexiform layer (IPL) contains synapses and connections between the ganglion cells and 
the cells of the inner nuclear layer (INL), which contains the cell bodies of bipolar cells, 
Müller cells, amacrine cells, and horizontal cells (Barrett et. al, 2019). These cells serve a 
number of functions including glial support, light-dark adaptation, and a number of 
complex signal integrations and modifications not yet fully understood in the current 
literature (Shekhar et. al., 2016). The outer plexiform layer (OPL) contains synapses 
between these cells and the photoreceptors, whose cell bodies are located in the outer 
nuclear layer (ONL). The outer limiting membrane separates the cells bodies of the 
photoreceptors from their outer and inner segments contained in the photoreceptor 
layer, where light signals are converted to electrical signals. Finally, the retinal pigment 




and serves a number of functions, including supplying nutrients to the photoreceptors 




Figure 2: Layers of the retina and corresponding cells types. Light passes through nine 
of the ten layers of the retina before contacting the photoreceptor layer, which converts 
light stimuli into electrical signals, starting a cascade of signaling cascade that ultimately 




Vasculature Supplying the Retina 
 
 The retina receives the majority of its blood supply from two sources, the central 
retinal artery (CRA) and the choriocapillaris. The choriocapillairis supplies oxygen and 
nutrients to the outer segments of the retina, including the RPE and the photoreceptor 
layer. It supplies small, fenestrated capillaries in the inner portion of the choroid, which 
contains the highest blood flow per unit of tissue in the entire human body (Spencer & 
Frasier, 2013). The CRA is a branch of the ophthalmic artery of the internal carotid, and 
enters the globe of the eye through the optic nerve head (ONH) alongside the optic 
nerve, and is the sole supply of perfusion for the inner retinal layer of the macula in 75% 
of humans. The first division of the CRA are the superior and inferior branching arteries, 
which further subdivide into temporal and nasal branching arteries.  In approximately 25% 
of humans, a cilioretinal artery emerges from the ONH as well, and supplies oxygen and 
nutrients to the macula (Varma et. al., 2013). Vessels emerging from the CRA do not 
anastomose with other vessels, therefore an occlusion of the CRA results in anoxia to 
the inner layers of the macula. These arteries supply two major capillary beds: the 
superficial capillary bed, which is located in the between the ganglion cell layer and the 
nerve fiber layer, and the deep capillary bed, which is situated in the INL. These capillary 
beds are not found in the foveal avascular zone, as they are displaced along with the 




regulation of fluid balance through these capillaries via the blood-retina-barrier (BRB), a 
tight meshwork of endothelia, tight junctions, basement membranes, and pericytes that 
regulate electrolyte balance and thus fluid movement into surrounding tissues. Disease 
and disfunction of the BRB can lead to macular edema, as is commonly seen in diabetics. 
The capillaries from the CRA form tributaries to the branched retinal veins which then 
coalesce into the central retinal vein (CRV). The CRV exits the globe through the ONH 
directly adjacent to the CRA.  
 
Central Retinal Vein Occlusions  
 
 Central Retinal Vein Occlusions (CRVOs) and Branched Retinal Vein Occlusions 
(BRVOs) are the most common occlusive injuries of the retina, and are the second most 
common vascular retinopathy after diabetic retinopathy (Karia, 2010). Globally, 
approximately 28 million individuals are affected by either CRVOs or BRVOs.  They can 
be further subdivided into ischemic occlusions and non-ischemic occlusions, which 
present in clinically distinct ways. (RVOs) in general present with a combination of 
painless vision loss, vascular tortuosity, optic disc swelling, cotton wool spots, retinal 
hemorrhaging, and macular edema. Glaucoma and ocular hypertension are commonly 
diagnosed with RVOs, although the exact association between these conditions, 




RVOs include Virchow’s Triad of thrombogenisis; hypercoagulability stasis, and 
endothelial damage. Underlying diseases that exacerbate or can cause any of these 
three classic factors are therefore also risk factors for the development of RVOs, such as 
diabetes mellitus, hypertension, atherosclerosis, and mutations affecting blood 
coagulability, such as prothrombin mutilations (Janssen et. al. 2005).   
 
Treatment of CRVOs 
 
 Treatment following the conformation of CRVOs and BRVOs is necessary to 
prevent further complications, such as neovascularization in the retina, cystoid macular 
edema, secondary neovascular glaucoma, and to is ultimately performed to preserve VA 
(Yeh et. al. 2005). Neovascularization often leads to the growth of tortuous, poorly 
formed vessels and ultimately, the breakdown of the BRB. This can exacerbate macular 
edema and lead to progressive deterioration of VA (Hykin et. al. 2019).  Often 
intravitreal injections of corticosteroids or anti-vascular epithelial growth factor (anti-
VEGF) drugs are used to prevent subsequent neovascularization caused by VEGF, which 
is released by endothelia in response to hypoxic conditions caused by ischemia. 
Panretinal photocoagulation has also been shown to be an effective intervention in 
preventing subsequent neovascularization secondary to RVOs, and is thought to also 




treatment options explored include the inhalation of concentrated oxygen (hyperoxia) 
(Arroyo et al., 2021) to assist in resolving ischemia and subsequently inhibit the release 
of VEGF, and the inhalation of carbogen, a mixture of 95% oxygen and 5% carbon 
dioxide to promote vasodilation and restore perfusion (Pournaras et. al., 2004). 
 
Central Retinal Artery Occlusions  
 
Central Retinal Artery Occlusions (CRAOs) are a relatively rare occlusive injury, 
with an incidence rate of approximately 1.9/100,000 people in the United States (Modi 
et al., 2017). CRAOS are akin to a stroke of the eye, as the CRA is the supply of nutrients 
and oxygen to the inner layers of the retina, particularly surrounding the macula. CRAOs 
present clinically as sudden, painless loss of vision in the affected eye. The central 
retinal artery is the primary and major blood supply to the inner retinal layers of the 
retina, therefore central retinal artery occlusions often result in severe decrease in VA in 
affected eyes (Chen et al., 2013). In animal models, irreversible damage to inner retinal 
layers from ischemia and anoxia occurred 240 minutes post-occlusion (Hayreh et al., 
2004). Risk factors for CRAOs are identical to risk factors for strokes and cardiovascular 
disease, and include age, arterial hypertension, diabetes mellitus, carotid artery disease, 
coronary artery disease, transient ischemic attacks (TIAs) or cerebral vascular accidents, 




most common associated signs upon examination of CRAO affected retinas include 
retinal opacity in the posterior pole (58%), cherry-red spot (90%), cattle trucking (19%), 
retinal arterial attenuation (32%), and optic disk edema (22%) and pallor (39%) (Scott, 
2017). Currently, there are no established treatments that alter the course of this 
disease; management of CRAOs focus primarily on the prevention of subsequent 
neovascularization and edema (Lee et al., 2013) (Chronopolous & Schutz, 2019).  
 
Figure 3: Fundus Photo of Early CRAO. Note the opacity surrounding the fovea 
associated with edema due to tissue damage stemming from anoxia. The central cherry 
red spot occurs in the avascular zone of the fovea, where the inner layer of the retina as 





In animal models, inhibition of platelet aggregating factors using ticlopidine has 
been shown to decrease the rate at which retinal vein occlusions are artificially induced, 
suggesting that these compounds may be useful as prophylactic agents against vascular 
occlusions (Arroyo et. al, 2001). The use of thrombolytic agents to resolve CRAOs have 
been associated with greater complications than benefits (Hakim & Hakim, 2019).  
CRAOs can be categorized further clinically into four subgroups: non-arteritic 
CRAOs (NA-CRAOs), transient NA-CRAOs, NA-CRAOs with cilioretinal artery sparing, and 
arteritic CRAOs (Hayreh, 2018). NA-CRAOs are the most common and account for 2/3 of 
all cases. They are the result of atherosclerotic disease, and occur due to blockage of the 
CRA by platelet fibrin, calcium, or cholesterol embolus. Transient NA-CRAOs are 
analogous to transient ischemic attacks, and have the best prognosis for preservation of 
visual acuity out of the 4 subgroups of CRAOS. They account for 15% of all CRAOs, and 
are thought to be a result of serotonin induced vasospasms dislodging atherosclerotic 
plaques. NA-CRAOs with cilioretinal artery sparing can occur in the roughly 25% of 
humans that receive perfusion to the macula from both the CRA and the cilioretinal 
artery, and in these cases, the macula is largely spared due to the dual blood supply 
(Hayreh, 2018). Finally, arteritic CRAOs account for approximately 4% of CRAOs and are 






Treatment of CRAOs 
 
 As mentioned previously, there is no single consensus on the treatment of 
CRAOs, and therefore multiple therapies have been proposed with mixed results. Non-
invasive treatments proposed include hyperbaric oxygen which may improve oxygen 
delivery to the retina, possibly sparing the macula of the acute effects of anoxia. 
Carbogen inhalation has also been proposed as a potential vasodilator that in theory 
may help spontaneously resolve the occlusion. Ocular massage therapies may also be 
administered in an attempt to dislodge emboli, as well as globe massage (Farris & 
Waymack, 2021).  
 As CRAOs are analogous to strokes of the eye, the use of thrombolytic agents, 
particularly tissue plasminogen activator (tPA) has been utilized and studied as a 
possible intervention, although its efficacy is debated. TPA is a naturally occurring 
fibrinolytic agent found in endothelial cells that lyses clots by converting plasminogen to 
plasmin. Plasmin in turn enzymatically degrades blood proteins, including fibrin clots.  
While some studies have reported promising results in vision sparing when 
administering tPA, others have reported no changes in outcomes. Furthermore, the risk 
of hemorrhagic stroke when administering tPA as well as the costs associated with the 
necessary observation and post treatment evaluation suggest that tPA administration is 




studies exploring the use of tPA in resolving CRAOs means that a consensus has not 
been reached, and it remains an area of potential future exploration (Bouisse et. al., 
2007). 
 Other therapies proposed in treated CRAOs are aimed at reducing intraocular 
pressure in an attempt to dislodge the emboli. This includes the administration of 
intravenous agents such as acetazolamide, a carbonic anhydrase inhibitor which in turn 
would lower the production of aqueous humor in the anterior chamber and therefore 
lower intraocular pressure (IOP). Topical antiglaucoma drops have also been proposed 
through similar mechanisms of action, as well as intravenous mannitol. Like other 
proposed therapies, results have been mixed (Cugatti et. al., 2013).  
 Preventative treatments for CRAOs include the monitoring and maintenance of a 
healthy diet and lifestyle aimed at reducing the risk of atherosclerosis. This includes 
regular exercise, a diet with a low glycemic index that is comprised primarily of fruits, 
vegetables, grains, low-fat or nonfat dairy products, fish, legumes, poultry, and lean 
meats, polyunsaturated fatty acids. Smoking cessation is also an important aspect of 
lowering risk factors associated with CRAOs due to the propensity endothelial damage 
caused by inhaled toxins (Mehta et. al., 2017). Hyperhomocystemia is another 
recognized risk factor for CRAOs through induced disfunction of endothelial cells, and 
therefore diets rich in folate, B6, and B12 are recommended as a preventative measure. 




atherosclerotic plaques, therefore preventative measures against CRAOs include the 
monitoring and appropriate interventions necessary to keep circulating low density 
lipoproteins at appropriate levels (Varma et. al., 2013). 
 
Other Retinopathies Affecting Retinal Vasculature 
 
 In developed countries, retinopathies affecting retinal vasculature are the 
leading cause of blindness (Brand, 2012). The three most common retinopathies of 
vasculature in the United States in order are diabetic macular edema (DME), CRVOs 
(previously discussed), and age-related macular degeneration (AMD). 
(1) Diabetic Macular Edema  
The Early Treatment Diabetic Retinopathy Study (ETDRS) defines Diabetic 
Macular Edema (DME) as retinal thickening or the presence of hard exudates within 1 
disk diameter of the macula. The term clinically significant macular edema (CSME) is 
used to describe macular edema that is characterized by any or a combination of the 
following:  edema is within 500 microns of the center of the macula, hard exudates are 
found within 500 microns of the center of the macula and is associated with retinal 
thickening, or retinal thickening is present in at least one disk diameter on the retina 
within one disk diameter of the center of the macula (ETDRS Study Research Group, 




and approximately 75,000 new cases are reported annually. In diabetics, DME is the 
leading cause of vision loss and blindness. While the exact pathogenesis of DME is 
unclear, it is widely accepted to stem from microvasculature injury and the disruption of 
the BRB, which eventually leads to an accumulation of fluid in between the layers of the 
retina (Bresnick, 1986). DME is generally a chronic condition, and results in vision loss in 
33% of individuals left untreated for a period of 3 or more years. The rate reported 
vision loss increases with patient age as well as duration of disease. 
Poorly managed hyperglycemia is the cardinal risk factor for the development of 
DME, as elevated glucose levels induce the formation of damaging oxidative free 
radicals and protein kinase C activation. This can lead to further induced injury via 
hypoxia, altered blood flow, ischemia, and inflammation. Injury to endothelia, hypoxia, 
and the breakdown of the BRB can induce neovascularization through activation of the 
VEGF pathway, which can in turn exacerbate underlying conditions and increase fluid 
deposition in the macula and periphery.  
In patients 60 years of age and older, DME is also associated with a significantly 
higher rate of posterior vitreous detachments (PVDs) when compared to non-diabetic 
CSME. This is thought to be related to the accumulation of advanced glycation end 
products (AGEs) leading to increased cross linkages in collagen fibrils along with 
hyperglycemia induced liquefaction of the vitreous gel. Standard imaging methods used 




Coherence Tomography (OCT) to confirm the presence of vascular leakage and macular 
edema respectively (Nasrallah et. al., 1998).  
Treatment of DME is similar to treatments of other vascular retinopathies. If 
CSME is not present, the recommended course of action is periodic and regular 
evaluation. In areas containing microaneurysms or diffuse ischemia, laser 
photocoagulation is recommended to prevent subsequent neovascularization and 
edema, though the exact criteria for which photocoagulation is recommended remains a 
point of debate (ETDRS Study Research Group, 1987). Intravitreal injections of 
corticosteroids or anti-VEGF compounds have been shown to significantly reduce 
vascular permeability and neovascularization in all vascular retinopathies and is 
therefore effective in treating the underlying causes of DME. 
(2) Age Related Macular Degeneration  
Age Related Macular Degeneration (AMD) is a progressive chronic disorder that 
affects the macula of older individuals, leading to a progressive loss in vision. AMD can 
be further subdivided into two groups, wet AMD and dry AMD, the former being 
characterized by the development of neovascularization. AMD prevalence is rare in 
individuals younger than 55 and is more common in individuals 75 years or older, and is 
globally the third leading cause of blindness before cataracts and glaucoma. While dry 
AMD is more common, wet AMD accounts for the vast majority of severe vision loss 




AMD begins through the deposition of lipids on Bruch’s membrane, the 
innermost layer of the choroid, and is thought to be due to defects in the RPE’s ability to 
clear cellular debris. The appearance of drusen, deposits of lipids, amyloid, complement 
factors, and other cellular debris is the earliest clinical sign of AMD, and appears as 
focal, white-yellow spots deep within the retina. Thickening and degeneration of Bruch’s 
membrane following can result in a significant barrier for fluid transport and lead to 
ischemia. The ischemia can lead to the activation of VEGF pathways and lead to 
subsequent neovascularization, which leads to wet AMD (Pauleikhoff, 1990).  
Confirming the diagnosis of AMD is usually done using OCT imaging and 
occasionally B-scans. To test for neovascularization in the retina, FA imaging is 
conducted. Wet AMD can also lead to choroidal neovascularization, in which case 
Indocyan- angiography is performed, as the dye is more suitable for the visualization of 
choriocapillary circulation that a fluorescein dye (Bowling and Kanski, 2015). Treatment 
for AMD involves preventing the development of wet AMD and neovascularization, and 







Figure 4: OCT Image of Clinically Significant Macular Edema. Note the fluid deposited 
between layers of the retina. Neovascularization secondary to a number of vascular 
retinopathies, including CRVO, DME, and wet AMD can lead to formation of CSME. 
 
Diagnostic Imaging and CRAOs 
 
 Currently there are a number of imaging techniques that can be utilized to help 
accurately diagnose vascular occlusions affecting the retina, including the diagnosis of 
CRAOs. The two most commonly used imaging techniques are optical coherence 
tomography (OCT) and fluorescein angiography (FA), each with their respective 
strengths and limitations. A relatively newer imaging technique, laser speckle 
flowgraphy (LSFG) has shown promise in providing quantitative data that OCT imaging 






(1) Optical Coherence Tomography 
Optical Coherence Tomography is a non-invasive imaging technique that allows 
for the visualization of cross-sectional areas of tissue to certain depths. Compared to 
other medical imaging such as ultrasound and magnetic resonance imaging, OCT 
imaging has the added benefit of acquiring significantly higher resolution images. OCT 
imaging utilizes incident light of the near infrared wavelength, which can penetrate 
tissue several hundred microns in depth, which is split into a reference beam of known 
length and a central or probe beam which is directed through the cornea and lens onto 
the retina. These beams are then reflected back onto a photodetector, where they can 
constructively interfere, destructively interfere, or a mixture of the two, and is recorded 
by a signal processor. The signal processor records both the light intensity and the depth 
from which the light is reflected, thus creating a high-resolution depth profile of the 
retina in a fashion similar to ultrasound imaging techniques (Aumann et. al., 2019). OCT 
imaging allows for fast, accurate visualization of the layers of the retina, choroid, sclera, 
and posterior vitreous, and allow accurate diagnoses of a number of retinopathies, 
including retinal detachments, retinal holes, epiretinal membranes, and macular edema. 
SPECTRALIS OCT, introduced in 2006 by Heidelberg Engineering, combines confocal laser 
scanning ophthalmoscopy and OCT to allow for high resolution angiography imaging as 
well (Gaulino et. al., 2019). OCT and OCT-angiography are noninvasive techniques that 




important limitation is that they cannot provide quantitative metrics relating to overall 
blood flow. 
 
Figure 5: OCT Image of Acute CRAO. On the left, the green line demarcates the cross 
section corresponding to the image on the right. Note the hyperreflectivity of the inner 
layers of the retina. Hyperreflectivity and edema in the inner layers is associated with 
widespread cell death due to anoxia leading to the inner layers losing their normally 
ordered structure. This leads to hyperreflectivity in OCT images, and can be viewed as 









Figure 6: OCT Image of Late CRAO. On the left, the green line demarcates the cross 
section corresponding to the image on the right. This OCT scan was taken 69 days after 




Figure 7: CRAO Central Thickness of Macula OCT Progression. Green areas represent 
healthy retinal thickness. Orange, red, and white areas show areas where retinal 
thickness is elevated due to edema. Blue areas represent areas of the retina that are 
thinner than what is considered normal. Panel A shows macular thickness as measured 
by OCT imaging approximately 2 days after reported vision loss. Edema is widespread, 
but spares the foveola (arrow) due to the lack of capillary beds. Panel B shows some 
regression of edema 14 days post incident. Panel C illustrates the regression of thickness 
from normal levels 69 days after CRAO as dead tissue is cleared. Early CRAOs present 
with marked edema and opacity surrounding the fovea due to ischemic necrosis of the 
inner layers of the retina. Gradually over time, this edema subsides as dead tissue is 
cleared, until finally, the overall thickness of the retina surrounding the fovea reduces to 





(2) Fluorescein Angiography (FA) 
Fluorescein Angiography (FA) is an imaging technique first utilized in the 1960s, and 
allows for real time visualization and assessment of retinal vasculature. Fluorescent dye 
is first injected intravenously, typically in the patient’s arm, while a fundus camera 
periodically takes photos of the patient’s retina. Within seconds, the fluorescein dye 
begins to perfuse through the retinal vasculature, and its transit through has been noted 
to occur in six distinct phases. The first phase is the early choroidal flush, as the dye 
reaches choriocapillary circulation before entering the arteriolar circulation supplying 
the inner retina. This is followed by the early arteriolar and later arteriolar phase as the 
dye is transmitted through the CRA and branched arteries. The final three phases in 
order are the capillary phase, and the late and early venous phases, after which the dye 
is no longer detectable by fundus photography (Dollery et. al., 1962). The absence of 
dye through certain areas of retinal vasculature can confirm the presence of an 
occlusion such as a CRAO. Vascular leakage can be confirmed through the visualization 
of extravascular dye. Since its initial introduction, FA has been established as the gold 
standard in diagnosing certain diseases, such as macular choroidal neovascularization. 
Since its advent, advances in fundus camera technology have allowed for up to 200 
degrees of horizontal view of the retina during FA imaging (Callaway & Mruthyunjaya, 







Figure 8: Fluorescein Angiography of CRAO. Panels A shows the healthy right eye of a 
patient. Panel B illustrates the findings of the left eye, confirming a CRAO. Note the  




Figure 9: Fundus Photography corresponding with FA Imaging. Fundus photography of 
the healthy right (OD) yields unremarkable findings. Fundus photography of the left eye 
(OS) confirms cherry red spot and peripheral opacity commonly associated with CRAOs. 
 
  
A major point of consideration when utilizing FA imaging is that, unlike OCT 
imaging and OCT angiographies, FA imaging is invasive as it requires an initial injection 




bolus at 20% concentration.  While side effects are typically uncommon, the potential 
for serious complications does exist. The most common reported side effect is nausea 
and vomiting, which is reported in approximately 5-10% of patients, and is much more 
prevalent in a patient’s first injection of fluorescent dye. The rate of incidence drops to 
nearly 0% if further injections for multiple imaging sessions is conducted. In a 
retrospective study examining the effects of FA injection in patients, other rare but 
serious potential side effects included urticaria and skin allergic reactions, respiratory 
allergic reactions including laryngeal edema, hypotensive shock, fatal myocardial 
infarction and cardiac arrest, basilar artery ischemia, and pyrexia. However, the 
complications noted were exceedingly rare, occurring at a rate lower than 1:1000; and 
FA imaging overall is considered a safe and useful diagnostic tool (Hayreh et. al., 1974). 
Similar to OCT imaging and OCT angiography, a major limitation in assessing perfusion 
and blood flow using FA imaging is the lack of quantitative data on flow measurements. 
(3) Laser Speckle Flowgraphy (LSFG) 
Laser speckle flowgraphy (LSFG) allows for the noninvasive, quantitative 
estimation of blood flow in the optic nerve head, choroid, retina and iris in vivo. (Orgul 
et al., 2010). LSFG imaging utilizes the LSFG-NAVI (Softcare Co., Ltd., Fukuoka, Japan), 
composed of a fundus camera, diode laser, infrared charged couple device (CCD), and 
CCD camera to calculate blur rate, which is an approximate reciprocal of the speckle 




other diagnostic techniques as well, when an optically rough surface is illuminated by 
incident light a speckle pattern is reflected based on consequent constructive and 
destructive interference of the incident wavelength. If surface is stationary, the speckle 
pattern remains constant, however if the object imaged is nonstationary, such as the 
case with erythrocyte movement through vasculature, the speckle pattern will produce 




Figure 10: Schematic Diagram of LSFG System. Basic components of LSFG system 
highlighted include fundus camera, diode laser, infrared charged couple device (CCD), 
and CCD camera. Adapted from Orgul et al., 2010 
Before beginning measurements, muscarinic eye drops such as tropicamide are 
administered to the patient to dilate the pupils. Alpha-adrenergic dilating drops such as 




in question, including the ONH (Sugiyama et al. 1992). The subject is given 5 -10 minutes 
of rest before beginning of measurements to ensure blood pressure and heartbeat are 
stable and at approximately rest values and then instructed to position the eye in 
question in front of the fundus camera and to align their gaze on the internal fixation 
target. The operator begins by focusing the fundus camera onto the area in question, in 
this case the ONH. Once in focus, the operator can begin LSFG scanning, which 
continuously takes measurements of speckle blur for the duration of the exam 
(Sugiyama et al., 1992). 
A major advantage of LSFG imaging when compared to more traditional imaging 
techniques such as FA and OCT is the ability to produce quantitative data that can then 
be utilized for interpatient and interpatient comparisons and statistical analyses. Mean 
Blur Rates (MBRs) as measured by LSFG scanning is the average blur rate calculated over 
the course of a single heartbeat.  MBRs calculated by LSFG imaging vary significantly 
between patients, but show low interpatient variability over time (Seto et. al., 2020). 
Therefore, a more descriptive measurement, relative blood flow (RBF), can be calculated 
as a ratio of MBRs between patient’s eyes, as this allows for the normalization of 






Figure 11: Laser Speckle Flowgraphy of Macula. Areas of high blood flow, including 
major vessels, are demarcated in red. Areas of low blood flow are demarcated in blue. 
Panel A illustrates the composite map of a CRAO affected right (OD) eye.  The ONH area 
with labels corresponding to the superior (S) , inferior (I), temporal (T), and nasal (N) 
quadrants are respectively highlighted. Panel B illustrates the composite map of the 
same patients' contralateral, healthy left (OS) eye. Panels C and D show the change in 










 The main goal of this study is to utilize the relatively new imaging instrument, 
LSFG, to quantitatively describe the loss of perfusion through the ONH of eyes affected 
by CRAOs. Control patients with bilateral, healthy eyes were used to establish low intra-
patient variability as well consistency in LSFG measurements over time. By showing no 
significant difference in MBRs calculated between control patient eyes, these results 
allowed for the use of RBF as a unitless, ratio measurement of diseased eyes versus 
healthy eyes. RBF is therefore a useful quantitative measure of loss of perfusion that 
traditional imaging techniques such as OCT and FA are unable to provide. In order to 
explore the possibility of recanalization or spontaneous resolution of the occlusion, we 
divided patients into temporal subgroups to determine if RBF values differed 
significantly based on the time LSFG scans were taken relative to the initial reported loss 
of vision. Lastly, statistical analysis was performed to determine if any meaningful return 







 This study was a prospective observational analysis of retinal blood flow in 
patients with central retinal artery occlusions. It was approved by the BIDMC IRB. 
Participants included seven CRAO patients with healthy contralateral eyes from Beth 
Israel Deaconess Medical Center Longwood Eye Clinic. Patients with cataracts or 
underlying, confounding retinopathies affecting either eye were excluded from the 
study. Those who met inclusion criteria were invited to participate in the study. Twenty 
control patients with no ocular disease were recruited to establish low intra-patient 
variability in longitudinal LSFG MBR measurements and statistically nonsignificant 
differences between MBRs of these patients’ eyes. 
LSFG-NAVI (Softcare Co., Ltd., Fukuoka, Japan) imaging instrument was used to 
calculate frame blur rates of the ONH area for the duration of three separate heartbeats 
per eye per patient per session. Frame blur rates over the duration of a single heartbeat 
was averaged to calculate MBR per heartbeat. RBF was calculated in CRAO patients by 
dividing diseased eye’s average MBR by the unaffected eye’s average MBR. For control 
RBF values the average left eye MBR was divided by the average right eye MBR. The 
resulting numerical value represents a ratio of blood flows between eyes, therefore an 






Age Sex CRAO Status OD CRAO Status OS 
69 M - + 
69 M + - 
70 M - + 
64 M - + 
72 M - + 
62 M + - 
65 M - + 
 
Table 1: Demographics of CRAO Patients. Seven patients (n=7) scanned with clinical 
history of unilateral CRAOs. Positive sign (+) indicates presence of CRAO. 
  
 VA was measured using the Snellen Chart, the most widespread diagnostic 
technique utilized in measuring VA (Ronquillo & Azzam, 2020) in standardized fashion, 
with normal vision defined as 20/20. Affected eyes were measured monocularly and 
results then converted to logarithm of minimum angle of resolution scale (logMAR) for 
statistical analysis.  
 Statistical analyses were conducted on measured variables to determine 
significance at an α = 0.05. Analysis of variance (ANOVA) was used to compare inter-
patient variability in MBR measurements and intra-patient MBR measurements, 
establishing the reliability of MBR and subsequently RBF as a quantitative measurement 
of blood flow. Welch’s one-tailed t- tests were used to compare the RBF values of CRAO 
patients and control patients to determine statistical significance, as well as RBF values 
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of CRAO patients divided into groups one-year post-incident and one-year pre-incident. 
Welch’s t -tests were also used to determine any statistically significant improvement in 
visual acuity between these groups of CRAO patients to determine if visual acuity and a 
return of blood flow hold correlation. All statistical analyses and figures were calculated 






 MBRs of control patients demonstrated high variability in measured values 
between patients (F19 = 14.60, P < 0.001). Measurement in a single control patient 
showed no statistically significant difference in MBR values between eyes (F1 = 0.83, P = 
0.37) or in imaging sessions conducted on separate dates (F1 = 0.012, P = 0.91). These 
results show high inter-patient variability in MBRs as measured by LSFG-NAVI, but low 
intra-patient variability, establishing reliability and consistency in blur measurements 
and allowing for the normalization of data using RBF to allow for ratio comparisons.  
 
 
Figure 12: MBR Measurements in Healthy Eyes. MBRs of control patients demonstrated 





Figure 13: MBR Measurements in Two Separate Imaging Sessions in The Healthy Eyes 
of a Single Patient. Measurement in a single control patient showed no statistically 
significant difference in MBR values between eyes (F1 = 0.83, P = 0.37) or in imaging 
sessions conducted on separate dates (F1 = 0.012, P = 0.91). These results establish the 
reproducibility of LSFG measurements over time and validate RBF comparisons as a 
unitless ratio measure that can be used to compare   
 
In control patients, RBF was calculated to be 1.02 (P = 0.88) indicating no 
significant difference in RBF between healthy eyes. In patients with unilateral CRAOs 
and healthy contralateral eyes, RBF was calculated to be 0.6650 ± 0.134 (P < 0.001), 
indicating on average a 33 percent loss in blood flow to the ONH in eyes with CRAOs.  
 Patients whose LSFG scans were taken within one year of reported vision loss 
had on average an RBF of 0.585, indicating on average a 42 percent loss in blood flow 
through the ONH. Patients whose LSFG scans were taken after one year of reported 
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vision loss had on average an RBF of 0.683, indicating on average a 31 percent loss in 
blood flow through the ONH.   
Figure 14: MBR of Affected Eye v Healthy Eye in CRAO Patients. Mean blur rates of 
affected eyes vs healthy eye of CRAO patients over the course of a heartbeat. Blur rates 











Figure 15: Average Relative Blood Flow in CRAO Patients vs Healthy Patients. In 
control patients, RBF was calculated to be 1.02 (P = 0.88) indicating no significant 
difference in RBF between healthy eyes. In CRAO patients, RBF was calculated to be 0.66 
± 0.13 (P < 0.001), indicating on average a 34 percent loss in blood flow to the ONH in 
eyes with CRAOs.  
 
When comparing the RBF values measured in patients whose LSFG scans were 
taken within a year of their vision loss versus in patients whose LSFG scans were taken 
after a year of reported vision loss, patients whose scans were taken after one year had 
on average a 0.10 greater RBF through the ONH of the diseased eye. However, due to 








Figure 16: Average Relative Blood Flow in CRAO Patients Scanned After 1 Year of 
Reported Vision Los vs. CRAO Patients Scanned Within 1 Year of Reported Vision Loss.  
Patients measured after one year have on average 0.10 greater RBF (0.683 v 0.585) 
which correlates to 10% greater blood flow through the ONH. However, due to small 
sample sizes, no statistical significance is associated with this increase at an α = 0.05 
(p = 0.6519). 
 
  
 Patients VA was measured the date of their first visit and every subsequent 
follow-up visit. Out of the seven patients measured, two did not return for follow-up 
visits, and therefore no data on VA one year after vision loss is reported. All patients 
measured had a VA of counting fingers (CF) or worse in their initial visit, with no 
significant improvement of vision in visits occurring after one year of reported vision 
loss. The average VA as measured by logMAR during initial visits was 2.07 ± 0.31. VA 
measurements of the five patients measured after one year of reported vision loss all 
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yielded CF, for an average VA of 1.9. These values showed no significant difference in VA 
in patients when comparing VA on initial visit and VA one year after reported vision loss 
at an α = 0.05 (p = 0.257). 
Age Sex Visual Acuity (Snellen) logMAR Conversion 
69 M CF 1.9 
69 M HM 2.3 
70 M CF 1.9 
64 M CF 1.9 
72 M CF 1.9 
62 M LP 2.7 
65 M CF 1.9 
 
Table 2: Initial Visual Acuity of CRAO Pts. CRAO patients VA were measured within 48 
hours of initial reported vision loss. All pts had VA of CF or worse, with an average VA of 
2.07 ± 0.31 when converting Snellen Chart values to logMAR values. 
 
Age Sex Visual Acuity (Snellen) logMAR Conversion 
69 M N/A* N/A 
69 M CF 1.9 
70 M CF 1.9 
64 M CF 1.9 
72 M CF 1.9 
62 M N/A* N/A 
65 M CF 1.9 
 
Table 3: Visual Acuity of CRAO Pts Measured After One Year of Reported Vision Loss. 
All patients measured had a VA of CF, or 1.9 when converted to logMAR values. Two 
patients did not follow-up one year after reported vision loss, and therefore no VA data 





 Our results confirm a dramatic drop in blood flow due occlusion as well 
as a severe loss in visual acuity normally associated with CRAOs and are consistent with 
previous publications (Chen et al., 2013) (Hayreh et al, 2004) (Datillo et al., 
2018).  Ultimately, this study established and utilized RBF ratio calculations to provide 
quantitative data on the degree of ischemia caused by CRAOs. RBF was shown to be a 
reliable and quantitative measure of ischemia noninvasively and descriptively in ways 
that FA and OCT imaging alone cannot, and can serve as a diagnostic tool to further our 
understanding of blood flow as it relates to CRAOs.  
 
RBF in the ONH was shown to be 33% lower on average in CRAO eyes, indicating 
a loss of a third of normal perfusion through the vasculature supplying the inner retina. 
To determine if perfusion in CRAO affected eyes returned over time, we subdivided RBF 
values based on the time LSFG scans were taken relative to when patients first reported 
vision loss. Patients scanned within one year of their reported vision loss had ten 
percent lower perfusion through the ONH when compared to patients scanned after 
one year of their reported vision loss .  When comparing RBF values of scans taken 
within one year of initial vision loss to scans taken after one year after, RBF was 
significantly lower in patients scanned within one year.  While these results did not yield 
statistical significance due to the limited sample size available (significant variation 
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within groups)?, they suggest that blood flow does return over time in CRAO patients, 
presumably as the occlusion resolves or re-canalizes. This increase in RBF was not 
correlated with a statistically significant increase in VA however, indicating that this loss 
in VA is permanent, consistent with the animal models describing massive irreversible 
retinal damage 240 minutes post-occlusion (Hayreh et al., 2004).  
This study includes limitations. A significant limiting factor was the small sample 
size; an increase in which would provide more robust statistical power and decrease the 
possibility of Type II errors. Longitudinal analysis proved to be limited due to the 
duration of the study, future studies could continue these analyses over longer periods 
of time, recruit a larger population of patients, and further divide patients into temporal 
subgroups in order to further investigate the return of blood flow with time. While RBF 
does provide novel, qualitative data, it is a unitless ratio comparison that cannot be 
directly correlated with concrete measurements of flow, such as ml/sec. This stems 
from the fact that blur as measured by the LSFG-NAVI is correlated to a change in 
speckle pattern (Shiga et al, 2014). While blur is directly correlated with blood flow, 
there is no method of converting this measurement into traditional measurements of 
flow.  
Further studies can expand on these findings by increasing sample size and 
longitudinal duration of examination and reexamination of patients affected not only by 
CRAOs, but other retinopathies that impact blood flow or vasculature in the retina. 
Studies can also be conducted to determine whether LSFG measurements can be used 
41 
as a diagnostic predictor of disease incident, possibly serving a diagnostic for 
intervention before CRAOs occur. 
42 
CONCLUSION 
In conclusion, this study has demonstrated the reliability of LSFG measurements 
in providing qualitative data where currently diagnostics are limited, and RBF values 
calculated indicate a severe reduction in blood flow through the ONH in CRAO affected 
eyes. While it does appear that blood flow through the ONH returns over time, 
significant variation coupled with low sample sizes yielded results that were not 
statistically significant at an α = 0.05, and therefore remains a point for future research 
interests.  We found no statistically significant return of VA over time, consistent with 
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